The APIS Team will be exhibiting at the 13th Annual World ADC in London, UK. Come and meet us at Booth 23.

At the 13th World ADC we will be discussing 3 key solutions that will help advance the development of antibody-drug conjugates:

Innovative synthetic ‘Clickmer’ high-affinity ligand binding technology, for the validation and translation of biomarker and drug assets into clinical utility.

APIS’ deep expertise and capabilities in platform agnostic IVD development of molecular & immunoassays for ultimate product realisation as IVD tests.

The new APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.

Interested in learning more? Use this link to contact us and schedule a meeting.